BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27343306)

  • 21. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
    Hahn HS; Yoon SG; Hong JS; Hong SR; Park SJ; Lim JY; Kwon YS; Lee IH; Lim KT; Lee KH; Shim JU; Mok JE; Kim TJ
    Int J Gynecol Cancer; 2009 Aug; 19(6):1068-73. PubMed ID: 19820370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Well-differentiated endometrial adenocarcinoma in an infertility patient with later conception. A case report.
    Kowalczyk CL; Malone J; Peterson EP; Jacques SM; Leach RE
    J Reprod Med; 1999 Jan; 44(1):57-60. PubMed ID: 9987742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma.
    Mao Y; Wan X; Chen Y; Lv W; Xie X
    Fertil Steril; 2010 Jan; 93(1):283-5. PubMed ID: 19962142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body mass index on clinicopathologic features, surgical morbidity and outcome in patients with endometrial cancer.
    Akbayır O; Corbacıoglu Esmer A; Numanoglu C; Cılesız Goksedef BP; Akca A; Bakır LV; Kuru O
    Arch Gynecol Obstet; 2012 Nov; 286(5):1269-76. PubMed ID: 22729137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conservative treatment of early endometrial cancer: preliminary results of a pilot study.
    Laurelli G; Di Vagno G; Scaffa C; Losito S; Del Giudice M; Greggi S
    Gynecol Oncol; 2011 Jan; 120(1):43-6. PubMed ID: 21040953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer.
    Dursun P; Erkanli S; Güzel AB; Gultekin M; Tarhan NC; Altundag O; Demirkiran F; Beşe T; Yildirim Y; Bozdag G; Yarali H; Simsek T; Ozcelik B; Ortaç F; Taskin S; Guvenal T; Ozgul N; Haberal A; Vardar MA; Dede M; Yenen M; Altintas A; Arvas M; Ayhan A
    Int J Gynaecol Obstet; 2012 Dec; 119(3):270-3. PubMed ID: 22921272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
    Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continued medical treatment for persistent early endometrial cancer in young women.
    Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
    Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate.
    Shirali E; Yarandi F; Eftekhar Z; Shojaei H; Khazaeipour Z
    Arch Gynecol Obstet; 2012 Mar; 285(3):791-5. PubMed ID: 21805142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women.
    Minig L; Franchi D; Boveri S; Casadio C; Bocciolone L; Sideri M
    Ann Oncol; 2011 Mar; 22(3):643-649. PubMed ID: 20876910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Six months response rate of combined oral medroxyprogesterone/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: a Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kang SB; Bae DS; Kim JW; Nam JH; Lim MC; Lee TS; Kim S; Paek J
    J Gynecol Oncol; 2019 Mar; 30(2):e47. PubMed ID: 30740964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
    Shikeli S; Gowri V; Rawahi TA
    JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
    Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
    Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system.
    Kim DH; Seong SJ; Kim MK; Bae HS; Kim M; Yun BS; Jung YW; Shim JY
    J Gynecol Oncol; 2017 Jan; 28(1):e1. PubMed ID: 27670255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women.
    Zhou H; Cao D; Yang J; Shen K; Lang J
    Int J Gynecol Cancer; 2017 Jul; 27(6):1178-1182. PubMed ID: 28562472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG).
    Lago V; Marina T; Laseca Modrego M; Gil-Ibañez B; Rodriguez JR; Domingo J; Minig L; Padilla-Iserte P; Arencibia Sánchez O; Sala Ferichola M; Munmanny M; Martín Salamanca B; Iacoponi S; Cabrera S; Coronado P; Utrilla-Layna J; Bataller Á; Fiol G; Corbalán S; Espinosa E; Gil-Moreno A; Domingo S;
    Arch Gynecol Obstet; 2022 Sep; 306(3):821-828. PubMed ID: 35122158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
    Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
    Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
    Wang HY; Shen L; Sun Z
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):237-41. PubMed ID: 16759457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer.
    Falcone F; Laurelli G; Losito S; Di Napoli M; Granata V; Greggi S
    J Gynecol Oncol; 2017 Jan; 28(1):e2. PubMed ID: 27670256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.